Retatrutide Cuts HbA1c by 1.9 Points and Weight by 15.3% in Phase 3 Diabetes Trial
Updated
Updated · The Guardian · Jun 7
Retatrutide Cuts HbA1c by 1.9 Points and Weight by 15.3% in Phase 3 Diabetes Trial
3 articles · Updated · The Guardian · Jun 7
Summary
Phase 3 data in 930 adults with type 2 diabetes showed weekly retatrutide lowered HbA1c by 1.7-1.9 percentage points over 40 weeks, versus 0.8 with placebo.
Weight loss reached 11.5%-15.3% on retatrutide, compared with 2.6% on placebo, while cholesterol and blood pressure also improved.
The once-weekly drug targets GLP-1, GIP and glucagon receptors, adding an energy-expenditure pathway beyond GLP-1-only drugs such as Ozempic and dual-action Mounjaro.
Serious adverse events were reported in 14 participants, including two on placebo, though most side effects were mild to moderate gastrointestinal symptoms that eased over time.
Researchers and outside experts called the results encouraging but said head-to-head trials and longer-term data are still needed to judge how retatrutide compares with existing diabetes treatments.